Get more replies from employers
Send a job-specific resume in minutes.
Zealand Pharma U.S., Inc. in Cambridge, MA is seeking a Scientist or Senior Scientist in Protein Purification and Analysis to deliver high-purity samples for discovery programs and structural biology studies, working hands-on with diverse purification technologies.
You will lead purification of recombinant proteins and bioconjugates, support analytical characterization by MS and biophysical methods, and help advance automated workflows within a new Molecular Platform Development team.
Does it excite you to be the go-to purification expert delivering high-purity samples for cutting-edge structural biology and mass spec studies? If this sounds like you, and you are ready to bring deep purification expertise to a new discovery organization, then you could be our new colleague.
As a Scientist or Senior Scientist in Protein Purification and Analysis, you will play an important scientific role supporting discovery programs, with a primary emphasis on high-quality purification of protein-based therapeutics and their bioconjugates. You will work hands-on with a broad range of modern protein purification technologies, with complementary analytical characterization, at the inception of our new Cambridge, MA research center.
This role suits a scientist with deep, hands-on expertise in protein and bioconjugate purification, scientific curiosity, and a desire to grow in scope and responsibility.
You bring deep, hands-on purification expertise and scientific curiosity, with a strong conceptual understanding of protein biophysics and stability principles. You thrive in a collaborative, multidisciplinary environment and are motivated to help shape purification workflows and a new research center from an early stage. You communicate scientific data, methods, and assumptions clearly and work effectively across cross-functional project teams.
You will join Molecular Platform Development, a new organization created to strengthen and advance diverse drug modality capabilities in metabolic disease, based at our new Cambridge, MA research center. The site is a highly collaborative, multidisciplinary discovery hub integrating computational research, chemistry, and biology, and is deeply connected to the Greater Boston life sciences ecosystem.
Let’s bond and be bold
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation.
Salary Range: $125,000 - $170,000
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.
Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts.
Learn more at www.zealandpharma.com.
Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.